Cover Image
市場調查報告書

特發性 (原發性) 高血壓:全球臨床實驗檢討

Idiopathic (Essential) Hypertension Global Clinical Trials Review, H2, 2017

出版商 GlobalData 商品編碼 247625
出版日期 內容資訊 英文 587 Pages
訂單完成後即時交付
價格
Back to Top
特發性 (原發性) 高血壓:全球臨床實驗檢討 Idiopathic (Essential) Hypertension Global Clinical Trials Review, H2, 2017
出版日期: 2017年10月31日 內容資訊: 英文 587 Pages
簡介

原因不明的高血壓便被稱為特發性高血壓,佔高血壓的95%。導致高血壓的致病因子因患者不同而會產生不同的障礙。特發性高血壓的症狀有頭痛、鼻血、呼吸急促、倦怠感、胸部疼痛等。診斷方面使用身體檢查、血壓檢測、尿液檢查、血液檢驗、心電圖等。治療方法依血壓不同各異,主要以藥物療法及改善生活習慣為主。企併症有動脈粥狀硬化性心血管疾病、心臟病發作、中風、心臟肥大、腎臟障礙等。

本報告提供特發性 (原發性) 高血壓的疼痛相關臨床研究最新趨勢分析,提供您疾病·治療方法概要,G7及E7各國的臨床實驗狀況,地區、PHASE、階段別的進行狀況,彙整有潛力的贊助商,各企業及研究機關的研究進行狀況,有潛力的藥劑比較等資訊。

簡介

  • 特發性 (原發性) 高血壓
  • 本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數量和平均實驗人數
    • 前五名國家的臨床實驗數量; 亞太地區
    • 前五名國家的臨床實驗數量; 歐洲
    • 主要國家的臨床實驗數量; 北美
    • 前五名國家的臨床實驗數量; 中東/非洲地區
    • 前五名國家的臨床實驗數量; 中南美

G7各國的臨床實驗數量: 特發性 (原發性) 高血壓 臨床實驗數量上心臟血管臨床實驗數量所佔的比例

Phase別臨床實驗數量: G7各國

G7各國的臨床實驗數量:Phase別

E7各國的臨床實驗數量: 特發性 (原發性) 高血壓 臨床實驗數量上心臟血管臨床實驗數量所佔的比例

Phase別臨床實驗數量: E7各國

E7各國的臨床實驗數量:Phase別

Phase別臨床實驗數量

  • Phase別的進展中臨床實驗數量

各進展狀況臨床實驗數量

評估項目臨床實驗數量別

未完成的臨床實驗

一定期間所採用的被實驗人數

贊助商的不同種類的臨床實驗數量

有潛力的贊助商

臨床實驗主要參加企業 - 特發性 (原發性) 高血壓 治療藥

有潛力的藥劑

臨床實驗簡介

  • 有代表性的企業臨床實驗概要
    • Novartis AG
    • C. H. Boehringer Sohn AG & Co. KG
    • 武田藥品工業
    • 第一三共
    • Merck & Co., Inc.
    • Medionics International Inc
    • Bayer AG
    • GlaxoSmithKline plc
    • Pfizer Inc.
    • Les Laboratoires Servier SAS
  • 有代表性的研究機關醫院臨床實驗概要
    • Institut de Recherches Internationales Servier
    • Regional Hospital Holstebro
    • National Heart, Lung, and Blood Institute
    • University of Erlangen-Nurnberg
    • University of Pavia
    • St. George's University of London
    • Central South University
    • 愛媛大學大學院醫學系研究科
    • 菰野健康福利醫院
    • 岡山大學大學院醫生牙齒藥學綜合研究科

5大臨床實驗簡介

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC4642CTIDB

GlobalData's clinical trial report, "Idiopathic (Essential) Hypertension Global Clinical Trials Review, H2, 2017" provides an overview of Idiopathic (Essential) Hypertension clinical trials scenario. This report provides top line data relating to the clinical trials on Idiopathic (Essential) Hypertension. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 4
  • Report Guidance 5
  • GlobalData Clinical Trials Report Coverage 6
  • Clinical Trials by Region 7
  • Clinical Trials and Average Enrollment by Country 8
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
  • Top Five Countries Contributing to Clinical Trials in Europe 11
  • Top Countries Contributing to Clinical Trials in North America 12
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
  • Top Five Countries Contributing to Clinical Trials in Central and South America 14
  • Clinical Trials by G7 Countries: Proportion of Idiopathic (Essential) Hypertension to Cardiovascular Clinical Trials 15
  • Clinical Trials by Phase in G7 Countries 16
  • Clinical Trials in G7 Countries by Trial Status 17
  • Clinical Trials by E7 Countries: Proportion of Idiopathic (Essential) Hypertension to Cardiovascular Clinical Trials 18
  • Clinical Trials by Phase in E7 Countries 19
  • Clinical Trials in E7 Countries by Trial Status 20
  • Clinical Trials by Phase 21
  • In Progress Trials by Phase 22
  • Clinical Trials by Trial Status 23
  • Clinical Trials by End Point Status 24
  • Subjects Recruited Over a Period of Time 25
  • Clinical Trials by Sponsor Type 26
  • Prominent Sponsors 27
  • Top Companies Participating in Idiopathic (Essential) Hypertension Therapeutics Clinical Trials 28
  • Prominent Drugs 30
  • Latest Clinical Trials News on Idiopathic (Essential) Hypertension 31
  • Sep 25, 2017: Daiichi Sankyo Announces Positive Top-line Results from Phase 3 Study in Japan of Esaxerenone for Treatment of Essential Hypertension 31
  • Clinical Trial Profile Snapshots 32

Appendix 585

  • Abbreviations 585
  • Definitions 585
  • Research Methodology 586
  • Secondary Research 586
  • About GlobalData 587
  • Contact Us 587
  • Source 587

List of Tables

List of Tables

  • Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials by Region, 2017* 7
  • Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
  • Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 10
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 11
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, North America, Top Countries, 2017* 12
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017* 13
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 14
  • Proportion of Idiopathic (Essential) Hypertension to Cardiovascular Clinical Trials, G7 Countries (%), 2017* 15
  • Idiopathic (Essential) Hypertension Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 16
  • Idiopathic (Essential) Hypertension Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 17
  • Proportion of Idiopathic (Essential) Hypertension to Cardiovascular Clinical Trials, E7 Countries (%), 2017* 18
  • Idiopathic (Essential) Hypertension Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 19
  • Idiopathic (Essential) Hypertension Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 20
  • Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials by Phase, 2017* 21
  • Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 22
  • Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials by Trial Status, 2017* 23
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, by End Point Status, 2017* 24
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 25
  • Idiopathic (Essential) Hypertension Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 26
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 27
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 29
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 30

List of Figures

List of Figures

  • Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials by Region (%), 2017* 7
  • Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
  • Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 10
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 11
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 12
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017* 13
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 14
  • Proportion of Idiopathic (Essential) Hypertension to Cardiovascular Clinical Trials, G7 Countries (%), 2017* 15
  • Idiopathic (Essential) Hypertension Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 16
  • Idiopathic (Essential) Hypertension Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 17
  • Proportion of Idiopathic (Essential) Hypertension to Cardiovascular Clinical Trials, E7 Countries (%), 2017* 18
  • Idiopathic (Essential) Hypertension Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 19
  • Idiopathic (Essential) Hypertension Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 20
  • Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials by Phase (%), 2017* 21
  • Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 22
  • Idiopathic (Essential) Hypertension Therapeutics, Global, Clinical Trials by Trial Status, 2017* 23
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, by End Point Status, 2017* 24
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 25
  • Idiopathic (Essential) Hypertension Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 26
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 27
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 28
  • Idiopathic (Essential) Hypertension Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 30
  • GlobalData Methodology 586
Back to Top